Intraperitoneal Paclitaxel

DRUG2 trials

Sponsors

ECOG-ACRIN Cancer Research Group, Magnus Nilsson

Conditions

Gastric AdenocarcinomaGastric Cancer Peritoneal MetastasesGastroesophageal Junction AdenocarcinomaPeritoneal Carcinomatosis

Phase 2

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

RecruitingNCT07001748

ECOG-ACRIN Cancer Research GroupGastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis

Start: 2025-08-19End: 2030-05-30Target: 148Updated: 2026-06-17

Phase 3

Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis

RecruitingNCT07304271

Magnus NilssonGastric Cancer Peritoneal Metastases

Start: 2025-11-05End: 2031-01-31Target: 262Updated: 2026-07-07

Related Papers

A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234.

Journal of Clinical Oncology2026-05-28